MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy): cardiac resynchronization therapy towards early management of heart failure by Breithardt, Günter




resynchronization therapy towards early
management of heart failure
Gu ¨nter Breithardt*
Medizinische Klinik und Poliklinik C (Kardiologie/Angiologie), Universita ¨tsklinikum Mu ¨nster, D-48129 Mu ¨nster, Germany
Online publish-ahead-of-print 22 September 2009
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A.J. Moss et al., published in the New England Journal of
Medicine, 2009; 361:1329–1338
Randomized clinical trials have ﬁrmly established the role of
cardiac resynchronization therapy (CRT) in chronic heart failure
patients in New York Heart Association (NYHA) class III or IV
who have left ventricular dysfunction and a prolonged QRS
complex. CRT improves symptoms, reduces the need for hospital-
izations, and improves survival by reversal of left ventricular remo-
delling and by slowing of disease progression.
In these CRT trials, patients were selected on the basis of the
degree of heart failure. COMPANION
1 included 86% class III and
14% class IV patients. CARE-HF included 94% NYHA class III and
6% class IV patients.
2 Thus, the data on the beneﬁcial effects of
CRT, based on large trials, are restricted to class III and to a lesser
degreetoclassIVpatients.Incontrast,inprimarypreventionimplan-
tablecardioverter deﬁbrillator (ICD)trials, the spectrum ofpatients
was broader. Although SCD-HeFT also selected heart failure
patients in class III (30%), the majority were in class II (70%).
3 The
twopost-myocardialinfarctiontrials,MADITandMADITII,included
an evenbroader spectrum ofheart failure patientsalthough primary
inclusion was on the basis of ejection fraction and history of prior
myocardial infarction. MADIT included 35% of patients in class I,
and 65% in class II–III.
4 In MADIT II, 37% of patients were in
NYHA class I, 35% in class II, 24% in class III, and 5% in class IV.
5
Since CRT induces progressive reverse left ventricular remodel-
ling and slows disease progression in patients with NYHA class III
or IV heart failure, it might also be beneﬁcial in patients with less
severe heart failure. Small studies have suggested that CRT may
indeed reverse left ventricular remodelling in NYHA class II
patients.
6–8 However, the impact of CRT in class I and II patients
on various outcome parameters has been a matter of debate.
Only recently, this issue was addressed in a larger randomized
trial that tested whether CRT is effective in reducing clinical end-
points in either asymptomatic (class I) but previously symptomatic,
or less symptomatic patients (class II). The REVERSE trial (REsyn-
chronization reVErses Remodeling in Systolic left vEntricular dys-
function)
9 randomly assigned 610 patients with NYHA functional
class I or II heart failure with a QRS duration of  0.12 s and a left
ventricular ejection fraction of  40% (mean 27%) who all received
a CRT device (with or without an ICD) to active CRT (CRT-ON,
n ¼ 419 patients) or control (CRT-OFF, n ¼ 191) for 12 months.
All patients had to be on a stable heart failure medication for at
least 3 months before enrolment. REVERSE failed to reach the
primary endpoint of a heart failure clinical composite response
which compared only the percentage of patients worsened (16%
worsened in CRT-On vs. 21% in CRT-Off, P ¼ 0.10). However,
patientsassignedtoCRT-ONexperiencedagreaterchangeinecho-
cardiographic left ventricular end-systolic volume index and other
measures of left ventricular remodelling. The time to ﬁrst hospital-
ization was signiﬁcantly delayed in patients randomized to CRT-ON
[hazards ratio (HR) 0.47, P ¼ 0.0.03]. The mortality rate at 1 year
was 2.2% for the CRT-ON group and 1.6% for the CRT-OFF
group (P ¼ 0.63). The authors concluded from this relatively small
trial thatCRT may delaydisease progression in heart failure patients
with less severe symptoms through left ventricular remodelling.
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beneﬁt of CRT
At the Hot Line Session of the 2009 ESC Congress, on 1 September
2009, Arthur Moss, Rochester, NY, presented for the ﬁrst time the
results of the MADIT-CRT trial (Multicenter Automatic Deﬁbrillator
Implantation Trial-Cardiac Resynchronization Therapy).
10 The trial
recruited a population similar to REVERSE, but three times more
patients were included (1820 vs. 610 patients). Both trials had
started in 2004. Recruitment in REVERSE ended in 2006 (follow-up
12 months) whereas MADIT-CRT, due to its larger patient
numbers, ended recruitment in 2008 (average follow-up 2.4 years).
During follow-up, 17.2% of patients in the resynchronization
group and 25.3% in the ICD group experienced the primary end-
point of all-cause mortality or a heart failure event, whichever
occurred ﬁrst [HR 0.66, 95% conﬁdence interval (CI) 0.52–0.84;
P ¼ 0.001), with similar beneﬁt in patients with ischaemic and non-
ischaemic cardiomyopathy.
10 Superiority of resynchronization
therapy was driven by a 41% reduction in the risk of a ﬁrst heart
failure event without an effect on the 3% annual mortality in
each treatment group. Resynchronization therapy was associated
with signiﬁcant reduction in left ventricular volumes and improve-
ment in ejection fraction.
Comparison between REVERSE
and MADIT-CRT: the same
message?
Apart from the number of patients included, the baseline clinical
characteristics such as age, gender, NYHA class I or II, ischaemic
vs. non-ischaemic, diabetes mellitus, use of angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),
b-blockers, diuretics, systolic and diastolic blood pressure, and
end-systolic and end-diastolic volumes on echocardiography
were almost identical. The inclusion criteria differed between
REVERSE and MADIT-CRT, respectively, with regard to QRS
width ( 0.12 vs.  0.13 s) and ejection fraction ( 0.40 vs.
 0.30). This may explain that for patients without and with
CRT, mean QRS duration in MADIT-CRT (159 and 158 ms,
respectively; A. Moss, personal communication) was slightly
longer than in REVERSE (154 and 153 ms).
9 This may be related
to the somewhat lower ejection fraction in MADIT-CRT (24% in
both groups) vs. 26.4 and 26.8% (in patients without and with
CRT) in REVERSE. The slightly higher mortality in MADIT-CRT
(3% in both groups) than in REVERSE (2.2% for CRT-ON and
1.6% for CRT-OFF; P ¼ 0.63) is in line with the slightly broader
QRS complexes and the somewhat lower ejection fraction in
MADIT-CRT.
Looking at subgroups may only help to generate hypotheses.
Doing so, it is remarkable that both trials did not show an effect
either on the ‘heart failure clinical composite response of worsen-
ing’ (as used in REVERSE) or for ‘death or heart failure’ (in
MADIT-CRT) in those patients with a QRS width ,0.15 s,
whereas a beneﬁt was found in both trials in those with a
broader QRS.
Although there were differences in endpoints between these
trials, both came up with a similar message, i.e. that in class I or
II patients CRT improves the function and structure of the left ven-
tricle, and leads to a decrease in the need for hospitalization due to
heart failure, but that it has no effect on mortality. Indeed, mor-
tality was low in both trials, as can be expected from a NYHA
class I and II population, despite the low ejection fraction of the
left ventricle.
In REVERSE, 85% (CRT-OFF group) and 82% (CRT-ON group)
received an ICD, whereas all patients in MADIT-CRT did so. Thus,
it can be assumed that the populations were comparable with pre-
vious ICD trials such as MADIT II and SCD-HeFT with regard to
ejection fraction and other clinical characteristics. Both trials
suggest—although MADIT-CRT presents the strongest
evidence—that CRT is able to halt the progression of heart
failure but does not have an effect on mortality (which was low
anyway), at least not during the follow-up period of 1 year
(REVERSE) or 2.4 years (MADIT-CRT).
Open issues
Is the evidence similarly strong for class I and II patients? This and
other questions might be answered by merging the original data
from both trials into a meta-analysis.
Patient characteristics were not much different from previous
ICD trials, especially with regard to ejection fraction. Should we
re-deﬁne the present guidelines for primary ICD implantation to
include CRT and, if so, to all patients with a QRS duration of
 0.12 s (or  0.13 s)? Or should there be a cut-off of 0.15 s
as suggested by the subgroup analyses in both trials? Should par-
ameters of dyssynchrony be added?
Another question is what makes some patients with a low ejec-
tion fraction less symptomatic than others with similar low ejection
fractions and why do they have a better clinical outcome.
Mortality in class I and II heart failure patients is low. However, if
progression of the disease in the long term is retarded by CRT,
does this translate into a lower mortality as the disease would nor-
mally progress and as long as no competing risks occur?
11 It may be
difﬁcult to ﬁnd an answer to this issue since the present data from
MADIT-CRT but also from REVERSE may make it at least difﬁcult if
not impossible to carry out another randomized trial with and
without CRT which, as a mortality trial, would require a very
large population.
Conclusions
CRT is an effective therapy in improving heart failure-related mani-
festations in patients with poor left ventricular function who fre-
quently are eligible for primary prevention ICD implantation with
an ischaemic or non-ischaemic aetiology and broad QRS com-
plexes of  0.12 s (REVERSE) or  0.13 s (MADIT-CRT) but
with no or only minimal symptoms.
The MADIT-CRT investigators are to be congratulated that they
have carried out this large and convincing trial.
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